Literature DB >> 34931243

A quantitative view of strategies to engineer cell-selective ligand binding.

Zhixin Cyrillus Tan1, Brian T Orcutt-Jahns2, Aaron S Meyer1,2,3,4.   

Abstract

A critical property of many therapies is their selective binding to target populations. Exceptional specificity can arise from high-affinity binding to surface targets expressed exclusively on target cell types. In many cases, however, therapeutic targets are only expressed at subtly different levels relative to off-target cells. More complex binding strategies have been developed to overcome this limitation, including multi-specific and multivalent molecules, creating a combinatorial explosion of design possibilities. Guiding strategies for developing cell-specific binding are critical to employ these tools. Here, we employ a uniquely general multivalent binding model to dissect multi-ligand and multi-receptor interactions. This model allows us to analyze and explore a series of mechanisms to engineer cell selectivity, including mixtures of molecules, affinity adjustments, valency changes, multi-specific molecules and ligand competition. Each of these strategies can optimize selectivity in distinct cases, leading to enhanced selectivity when employed together. The proposed model, therefore, provides a comprehensive toolkit for the model-driven design of selectively binding therapies.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34931243      PMCID: PMC8730367          DOI: 10.1093/intbio/zyab019

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  48 in total

1.  Isolating and engineering human antibodies using yeast surface display.

Authors:  Ginger Chao; Wai L Lau; Benjamin J Hackel; Stephen L Sazinsky; Shaun M Lippow; K Dane Wittrup
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity.

Authors:  Jared Francis Stefanick; David Thomas Omstead; Tanyel Kiziltepe; Basar Bilgicer
Journal:  Nanoscale       Date:  2019-03-07       Impact factor: 7.790

3.  Tuning the membrane selectivity of antimicrobial peptides by using multivalent design.

Authors:  Zhigang Liu; Anne W Young; Po Hu; Amanda J Rice; Chunhui Zhou; Yingkai Zhang; Neville R Kallenbach
Journal:  Chembiochem       Date:  2007-11-23       Impact factor: 3.164

4.  Mechanisms of noncanonical binding dynamics in multivalent protein-protein interactions.

Authors:  Wesley J Errington; Bence Bruncsics; Casim A Sarkar
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-27       Impact factor: 11.205

Review 5.  Multispecific drugs herald a new era of biopharmaceutical innovation.

Authors:  Raymond J Deshaies
Journal:  Nature       Date:  2020-04-15       Impact factor: 49.962

6.  Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro.

Authors:  Eda I Altiok; Jorge L Santiago-Ortiz; Felicia L Svedlund; Aline Zbinden; Amit K Jha; Deepika Bhatnagar; Peter Loskill; Wesley M Jackson; David V Schaffer; Kevin E Healy
Journal:  Biomaterials       Date:  2016-03-12       Impact factor: 12.479

7.  A general model of multivalent binding with ligands of heterotypic subunits and multiple surface receptors.

Authors:  Zhixin Cyrillus Tan; Aaron S Meyer
Journal:  Math Biosci       Date:  2021-10-09       Impact factor: 2.144

8.  Cancer Cells Upregulate NRF2 Signaling to Adapt to Autophagy Inhibition.

Authors:  Christina G Towers; Brent E Fitzwalter; Daniel Regan; Andrew Goodspeed; Michael J Morgan; Chang-Wei Liu; Daniel L Gustafson; Andrew Thorburn
Journal:  Dev Cell       Date:  2019-08-01       Impact factor: 12.270

9.  Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing.

Authors:  Andrew L Paek; Julia C Liu; Alexander Loewer; William C Forrester; Galit Lahav
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

10.  Integrin αvβ3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis.

Authors:  Lynn M Knowles; Lisa A Gurski; Charlotte Engel; James R Gnarra; Jodi K Maranchie; Jan Pilch
Journal:  Cancer Res       Date:  2013-08-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.